Sassoon doctors pull off Pune’s first nCoV plasma therapy recovery

Modesto Morganelli
Mag 24, 2020

At least 25 COVID-19 patients, who are in a semi-critical condition at Pune's government-run Sassoon General Hospital, will be administered tocilizumab, a drug which has proven effective in treating the infection, an official said on Friday.

A COVID-19 patient has recovered from the disease after he was given plasma-therapy, Pune's Sasoon Hospital said in a statement. The blood of a person who has recovered from Covid-19 develops antibodies to battle the virus.

The patients are undergoing treatment at Mugda Medical College and Hospital, Combined Military Hospital (CMH), Central Police Hospital, Bangladesh Specialized Hospital, Square Hospitals Ltd, Sheikh Hasina National Institute of Burn and Plastic Surgery, and Impulse Hospital in the capital.

A 47-year-old woman, who had co-morbid conditions such as hypertension, hyperthyroid and obesity and who was in critical condition, was given convalescent plasma therapy twice on May 10 and 11.

A special task force of specialist doctors, set up under the chairmanship of Dr D B Kadam, recommended tocilizumab for COVID-19 patients in case their condition worsens, he said. On May 20, the plasma was infused in another patient. As per the Indian Council of Medical Research (ICMR), hospitals and institutions planning to provide the treatment should do so using protocols that have been cleared by the Institutional Ethics Committee.

The DMCH authorities have urged all recovered patients to donate plasma so that it can be used for the treatment of critically ill Covid-19 patients.

He and his wife were the first Covid-19 patients reported in the state.

She has been shifted out of the Covid ward but not been discharged yet. This is the city's first successful plasma therapy recovery.

Covid-19, a severe acute respiratory illness caused by a new strain of coronavirus, has claimed 408 lives and infected 28,511 people in Bangladesh as of Thursday.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE